Mergers, Negotiation and Pharmaceutical - Investment Banking Today

From Mergers to Acquisitions: How to Successfully Execute a Corporate Restructuring Plan

Devensoft

MAY 25, 2023

Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan.

Corporation

Corporation Mergers Mergers and Acquisitions Acquisitions

Learning Old Lessons From Recent Life Sciences Earnout Disputes: Above All Else, Words Matter

Cooley M&A

OCTOBER 24, 2024

Alexion Pharmaceuticals (Del. September 2024), the Delaware Chancery Courts found buyers liable for failure to comply with negotiated earnout covenants – and in the latter case, awarded the plaintiffs more than $1 billion in damages. In both Fortis v. Johnson & Johnson (Del. September 2024) and SRS v.

Mergers and Acquisitions

Mergers and Acquisitions Mergers Negotiation Sale

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

How2Exit

MARCH 31, 2024

Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?

Business

Business Mergers and Acquisitions Securities M&A

Managing Product Shortages through Strategic M&A: Building a Resilient Supply Chain

Sun Acquisitions

AUGUST 22, 2024

To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). Larger, consolidated companies can negotiate better terms with suppliers, secure more favorable contracts, and reduce per-unit production costs.

M&A

M&A Management Mergers and Acquisitions Food

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement. Fresenius Kabi AG , C.A.

Mergers and Acquisitions

Mergers and Acquisitions Mergers Business Pharmaceutical

The Cooley Outlook for 2018 M&A

Cooley M&A

FEBRUARY 8, 2018

One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. Approval of gross-ups in connection with a transaction typically involves a prior negotiation with the buyer.

M&A

M&A Mergers and Acquisitions Mergers Negotiation

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

SEPTEMBER 19, 2023

For example, while a pharmaceutical company focused solely on shareholder value might prioritize high-margin drugs for rare conditions, a stakeholder-oriented approach might consider affordability and broader societal health needs , as seen with Gilead's approach to its HIV medications.

Corporation

Corporation Private Equity Mergers and Acquisitions Corporate Finance

When Approval for a Drug “Indication” Gets Murky: Drafting Milestones to Avoid Disputes

Cooley M&A

APRIL 7, 2017

The court agreed with Gilead, based primarily on a review of the parties’ drafting and negotiating history, which was corroborated by the parties’ contemporaneous statements made after the European Commission approved the deal. Throughout the trial, it was evident that the word had various meanings during the negotiations.

Mergers and Acquisitions

Mergers and Acquisitions Negotiation Pharmaceutical IT

Unleashing Synergy: A Guide to Strategic Integration and Value Amplification for Internal Business Groups

Devensoft

AUGUST 24, 2023

By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes. Short on time? Limited on time?

Business

Business Collaboration Mergers and Acquisitions Management

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A

M&A Mergers and Acquisitions Pharmaceutical Mergers

Mergers and Acquisitions in the Age of Trump: Opportunities and Challenges

MergersCorp M&A International

NOVEMBER 16, 2024

His presidency brought with it a unique set of policies and attitudes that would directly influence the realm of mergers and acquisitions (M&A). These regulatory rollbacks naturally benefitted companies considering mergers and acquisitions. as a favorable destination for investment. Foreign companies sought to acquire U.S.

Mergers and Acquisitions

Mergers and Acquisitions Mergers Acquisitions M&A

Antitrust Trends to Look Out for in 2022

Cooley M&A

JANUARY 21, 2022

Procedural upheavals have swept the merger review process, erecting new hurdles that merging parties must leap over, from the “temporary” suspension of early termination to the FTC’s issuance of pre-consummation “warning letters.” Increasing procedural hurdles to merger review. Withdrawal of 2020 Vertical Merger Guidelines.

Mergers and Acquisitions

Mergers and Acquisitions Mergers Pharmaceutical IT

Antitrust 2017: Trends and Developments to Watch

Cooley M&A

JANUARY 18, 2017

Uncertainty over how vigorous merger enforcement will be in the Trump Administration. The Obama Administration went out with a bang in 2016 on the merger enforcement front in potential reaction to criticism from the left that previous enforcement had been lax. year tenure at the agency. Penn State Hershey.

Mergers and Acquisitions

Mergers and Acquisitions Pharmaceutical Mergers Investment

Investment Banking Today

From Mergers to Acquisitions: How to Successfully Execute a Corporate Restructuring Plan

Learning Old Lessons From Recent Life Sciences Earnout Disputes: Above All Else, Words Matter

Trending Sources

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

Managing Product Shortages through Strategic M&A: Building a Resilient Supply Chain

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

The Cooley Outlook for 2018 M&A

Cooley’s 2022 Life Sciences M&A Year in Review

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

When Approval for a Drug “Indication” Gets Murky: Drafting Milestones to Avoid Disputes

Unleashing Synergy: A Guide to Strategic Integration and Value Amplification for Internal Business Groups

Cooley’s 2021 Life Sciences M&A Year in Review

Mergers and Acquisitions in the Age of Trump: Opportunities and Challenges

Antitrust Trends to Look Out for in 2022

Antitrust 2017: Trends and Developments to Watch

Stay Connected